Beta Bionics, Inc. (NASDAQ:BBNX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) have earned a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $22.91.

A number of equities analysts have weighed in on BBNX shares. Wall Street Zen upgraded shares of Beta Bionics from a “sell” rating to a “hold” rating in a research report on Saturday, September 19th. Bank of America upped their price target on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. The Goldman Sachs Group raised their price target on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. UBS Group reiterated a “buy” rating and issued a $25.00 price objective on shares of Beta Bionics in a report on Tuesday, September 15th. Finally, Wells Fargo & Company initiated coverage on Beta Bionics in a research note on Wednesday, September 23rd. They set an “overweight” rating and a $28.00 price objective for the company.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: The lawsuit alleges that Beta Bionics and certain executives misled investors about regulatory and product-quality issues involving the company’s automated insulin-delivery system, iLet. The allegations have not been proven in court. BBNX Investor Deadline article
• Negative Sentiment: According to one investor notice, the complaint contends that SEC filings characterized an FDA Warning Letter as identifying quality-management “non-conformities” while allegedly failing to disclose hundreds of unreported iLet complaints involving potentially life-threatening hypoglycemia. Such claims raise additional regulatory, product-liability and reputational risks. BBNX Shareholder Alert article
• Negative Sentiment: The action covers investors who purchased BBNX shares from July 30, 2025, through February 24, 2026, a period during which the lawsuit says surprise disclosures about FDA concerns caused sharp share-price declines. Continued litigation could create legal costs, management distraction and uncertainty around the iLet business. BBNX Investor Lawsuit article
• Neutral Sentiment: Several firms, including Rosen Law Firm, Kaplan Fox, Berger Montague and Faruqi & Faruqi, are soliciting affected investors before the November 3 lead-plaintiff deadline. These notices repeat the same case details and do not represent a new operating or financial update from Beta Bionics. Rosen Law Firm notice

Beta Bionics Trading Down 4.6%

BBNX opened at $20.52 on Tuesday. Beta Bionics has a 12-month low of $8.80 and a 12-month high of $32.71. The firm has a 50 day moving average of $18.22 and a two-hundred day moving average of $14.51. The firm has a market capitalization of $923.19 million, a PE ratio of -12.44 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $32.01 million for the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. As a group, analysts predict that Beta Bionics will post -2.06 EPS for the current fiscal year.

Insider Transactions at Beta Bionics

In other news, insider Steven Russell sold 4,221 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $80,663.31. Following the completion of the sale, the insider owned 169,628 shares of the company’s stock, valued at $3,241,591.08. This represents a 2.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mike Mensinger sold 2,650 shares of the company’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the sale, the insider directly owned 177,390 shares of the company’s stock, valued at $3,902,580. The trade was a 1.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 97,327 shares of company stock valued at $1,900,019. Insiders own 5.30% of the company’s stock.

Institutional Trading of Beta Bionics

Several large investors have recently bought and sold shares of the business. Squarepoint Ops LLC purchased a new position in Beta Bionics in the 2nd quarter worth approximately $2,524,000. Bank of America Corp DE purchased a new stake in shares of Beta Bionics in the second quarter valued at approximately $8,566,000. Man Group plc purchased a new stake in shares of Beta Bionics in the second quarter valued at approximately $419,000. Legal & General Group Plc acquired a new stake in shares of Beta Bionics in the second quarter valued at approximately $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Beta Bionics in the second quarter valued at approximately $172,000.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.